 Jia Liu
Concepts (163)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myxoma virus | 13 | 2017 | 14 | 2.710 |
Why?
| | Viral Proteins | 12 | 2017 | 156 | 2.650 |
Why?
| | Poxviridae | 5 | 2019 | 7 | 2.210 |
Why?
| | Proteins | 4 | 2017 | 345 | 1.250 |
Why?
| | Host Specificity | 3 | 2017 | 5 | 0.950 |
Why?
| | Genetic Vectors | 4 | 2019 | 125 | 0.860 |
Why?
| | Myxomatosis, Infectious | 3 | 2013 | 3 | 0.770 |
Why?
| | Virus Replication | 4 | 2016 | 140 | 0.750 |
Why?
| | Genetic Therapy | 3 | 2019 | 114 | 0.750 |
Why?
| | Antiviral Agents | 3 | 2014 | 173 | 0.740 |
Why?
| | Oncolytic Viruses | 5 | 2014 | 11 | 0.720 |
Why?
| | Genetic Engineering | 2 | 2019 | 24 | 0.680 |
Why?
| | Virus Cultivation | 1 | 2019 | 4 | 0.660 |
Why?
| | Viral Tropism | 3 | 2013 | 5 | 0.640 |
Why?
| | Host-Pathogen Interactions | 2 | 2016 | 135 | 0.570 |
Why?
| | Immunity, Innate | 2 | 2014 | 105 | 0.550 |
Why?
| | Rabbits | 9 | 2018 | 374 | 0.530 |
Why?
| | Animals | 23 | 2024 | 13246 | 0.500 |
Why?
| | Transcription, Genetic | 1 | 2016 | 369 | 0.490 |
Why?
| | Protein Biosynthesis | 1 | 2016 | 254 | 0.470 |
Why?
| | Interleukin-15 | 2 | 2014 | 16 | 0.460 |
Why?
| | Adenoviridae | 2 | 2008 | 51 | 0.400 |
Why?
| | Intracellular Signaling Peptides and Proteins | 4 | 2017 | 143 | 0.360 |
Why?
| | Virulence Factors | 1 | 2011 | 78 | 0.350 |
Why?
| | Immunologic Factors | 1 | 2010 | 114 | 0.340 |
Why?
| | Cornea | 1 | 2008 | 52 | 0.320 |
Why?
| | RNA, Catalytic | 1 | 2008 | 3 | 0.320 |
Why?
| | Herpesvirus 1, Human | 1 | 2008 | 15 | 0.310 |
Why?
| | Dependovirus | 1 | 2008 | 101 | 0.300 |
Why?
| | Oncolytic Virotherapy | 3 | 2012 | 17 | 0.300 |
Why?
| | Cell Line | 5 | 2019 | 1021 | 0.280 |
Why?
| | Cell Line, Tumor | 6 | 2024 | 1416 | 0.280 |
Why?
| | HeLa Cells | 2 | 2017 | 260 | 0.250 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2024 | 39 | 0.240 |
Why?
| | Kinetics | 3 | 2012 | 631 | 0.230 |
Why?
| | Mice | 10 | 2024 | 5759 | 0.220 |
Why?
| | Mammals | 2 | 2013 | 58 | 0.220 |
Why?
| | Evolution, Molecular | 2 | 2013 | 99 | 0.210 |
Why?
| | Humans | 17 | 2024 | 50208 | 0.200 |
Why?
| | Colorectal Neoplasms | 1 | 2024 | 236 | 0.190 |
Why?
| | Virulence | 2 | 2012 | 173 | 0.180 |
Why?
| | Poxviridae Infections | 2 | 2011 | 4 | 0.180 |
Why?
| | Drug Evaluation, Preclinical | 2 | 2019 | 143 | 0.180 |
Why?
| | Vero Cells | 1 | 2019 | 45 | 0.160 |
Why?
| | Transgenes | 1 | 2019 | 54 | 0.160 |
Why?
| | Protein Structure, Tertiary | 2 | 2017 | 253 | 0.160 |
Why?
| | Transduction, Genetic | 2 | 2008 | 45 | 0.160 |
Why?
| | Survival Analysis | 2 | 2011 | 666 | 0.150 |
Why?
| | Recombinant Fusion Proteins | 2 | 2014 | 186 | 0.140 |
Why?
| | Cytoplasmic Granules | 1 | 2016 | 25 | 0.140 |
Why?
| | HEK293 Cells | 1 | 2017 | 224 | 0.140 |
Why?
| | Gene Knockout Techniques | 2 | 2013 | 40 | 0.130 |
Why?
| | Stress, Physiological | 1 | 2016 | 170 | 0.130 |
Why?
| | Interleukin-15 Receptor alpha Subunit | 1 | 2014 | 2 | 0.120 |
Why?
| | RNA-Binding Proteins | 2 | 2013 | 123 | 0.120 |
Why?
| | eIF-2 Kinase | 1 | 2013 | 9 | 0.110 |
Why?
| | Multigene Family | 1 | 2013 | 56 | 0.110 |
Why?
| | Antineoplastic Agents | 2 | 2012 | 1186 | 0.110 |
Why?
| | Gene Deletion | 2 | 2012 | 270 | 0.110 |
Why?
| | DEAD-box RNA Helicases | 1 | 2013 | 34 | 0.110 |
Why?
| | Adaptation, Biological | 1 | 2012 | 10 | 0.110 |
Why?
| | Disease Models, Animal | 1 | 2018 | 1458 | 0.110 |
Why?
| | Monocytes | 1 | 2013 | 131 | 0.110 |
Why?
| | Dog Diseases | 1 | 2012 | 9 | 0.110 |
Why?
| | Tumor Suppressor Proteins | 1 | 2013 | 128 | 0.100 |
Why?
| | Vaccinia virus | 1 | 2012 | 6 | 0.100 |
Why?
| | Virus Assembly | 1 | 2012 | 4 | 0.100 |
Why?
| | Gene Order | 1 | 2012 | 13 | 0.100 |
Why?
| | Neoplasms | 2 | 2012 | 1249 | 0.100 |
Why?
| | Gene Expression Regulation, Viral | 1 | 2012 | 48 | 0.100 |
Why?
| | Deoxycytidine | 1 | 2012 | 28 | 0.100 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2012 | 38 | 0.100 |
Why?
| | Dendritic Cells | 1 | 2012 | 133 | 0.100 |
Why?
| | Neoplasm Proteins | 1 | 2013 | 324 | 0.090 |
Why?
| | Ependyma | 1 | 2010 | 3 | 0.090 |
Why?
| | Melanoma, Experimental | 1 | 2011 | 45 | 0.090 |
Why?
| | Tumor Virus Infections | 1 | 2011 | 42 | 0.090 |
Why?
| | Sirolimus | 1 | 2011 | 62 | 0.090 |
Why?
| | Immunotherapy, Adoptive | 1 | 2011 | 157 | 0.080 |
Why?
| | Macrophage Activation | 1 | 2009 | 25 | 0.080 |
Why?
| | Pancreatic Neoplasms | 1 | 2012 | 208 | 0.080 |
Why?
| | Epithelium, Corneal | 1 | 2008 | 9 | 0.080 |
Why?
| | Organ Culture Techniques | 1 | 2008 | 48 | 0.080 |
Why?
| | Plasmids | 1 | 2009 | 161 | 0.080 |
Why?
| | Organ Specificity | 1 | 2008 | 108 | 0.080 |
Why?
| | Green Fluorescent Proteins | 1 | 2008 | 91 | 0.080 |
Why?
| | Immunotherapy | 1 | 2010 | 240 | 0.080 |
Why?
| | Herpes Simplex | 1 | 2008 | 21 | 0.080 |
Why?
| | Chickens | 1 | 2008 | 110 | 0.080 |
Why?
| | Ganglia, Spinal | 1 | 2008 | 48 | 0.080 |
Why?
| | Foot | 1 | 2008 | 42 | 0.080 |
Why?
| | DNA, Viral | 1 | 2008 | 134 | 0.070 |
Why?
| | Brain Neoplasms | 1 | 2011 | 288 | 0.070 |
Why?
| | Spinal Cord | 1 | 2008 | 177 | 0.070 |
Why?
| | Proteomics | 1 | 2009 | 330 | 0.070 |
Why?
| | Mice, Knockout | 2 | 2024 | 846 | 0.070 |
Why?
| | Macrophages | 1 | 2009 | 363 | 0.070 |
Why?
| | Survival Rate | 1 | 2009 | 901 | 0.070 |
Why?
| | Diabetes Mellitus | 1 | 2008 | 286 | 0.060 |
Why?
| | Protein Binding | 1 | 2024 | 665 | 0.050 |
Why?
| | Brain | 1 | 2010 | 1328 | 0.050 |
Why?
| | Membrane Proteins | 1 | 2024 | 353 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-akt | 2 | 2012 | 157 | 0.050 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2012 | 388 | 0.040 |
Why?
| | Immunity | 1 | 2018 | 35 | 0.040 |
Why?
| | Immune System | 1 | 2018 | 43 | 0.040 |
Why?
| | Biological Evolution | 1 | 2018 | 32 | 0.040 |
Why?
| | Mice, Inbred C57BL | 2 | 2011 | 1819 | 0.030 |
Why?
| | DNA, Recombinant | 1 | 2014 | 15 | 0.030 |
Why?
| | Cell Count | 1 | 2014 | 149 | 0.030 |
Why?
| | Killer Cells, Natural | 1 | 2014 | 107 | 0.030 |
Why?
| | Gene Duplication | 1 | 2013 | 15 | 0.030 |
Why?
| | Interferon Type I | 1 | 2013 | 25 | 0.030 |
Why?
| | Sequence Alignment | 1 | 2013 | 122 | 0.030 |
Why?
| | Disease Susceptibility | 1 | 2013 | 89 | 0.030 |
Why?
| | Bayes Theorem | 1 | 2013 | 109 | 0.030 |
Why?
| | Genome | 1 | 2013 | 65 | 0.030 |
Why?
| | Toll-Like Receptor 7 | 1 | 2012 | 2 | 0.030 |
Why?
| | Chloroquine | 1 | 2012 | 10 | 0.030 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2012 | 75 | 0.030 |
Why?
| | Phylogeny | 1 | 2013 | 234 | 0.030 |
Why?
| | Dogs | 1 | 2012 | 185 | 0.030 |
Why?
| | Myeloid Differentiation Factor 88 | 1 | 2012 | 33 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2014 | 339 | 0.030 |
Why?
| | Interferon-alpha | 1 | 2012 | 48 | 0.030 |
Why?
| | Luminescent Measurements | 1 | 2012 | 15 | 0.030 |
Why?
| | Amino Acid Sequence | 1 | 2013 | 586 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2013 | 487 | 0.020 |
Why?
| | Cell Death | 1 | 2012 | 182 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2012 | 140 | 0.020 |
Why?
| | Mice, Nude | 1 | 2012 | 254 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2012 | 212 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2012 | 166 | 0.020 |
Why?
| | Melanoma | 1 | 2014 | 290 | 0.020 |
Why?
| | Blotting, Western | 1 | 2012 | 601 | 0.020 |
Why?
| | Phosphorylation | 1 | 2012 | 534 | 0.020 |
Why?
| | Injections, Intraventricular | 1 | 2010 | 14 | 0.020 |
Why?
| | Down-Regulation | 1 | 2012 | 349 | 0.020 |
Why?
| | Membrane Glycoproteins | 1 | 2012 | 246 | 0.020 |
Why?
| | Histocytochemistry | 1 | 2010 | 47 | 0.020 |
Why?
| | Genes, Reporter | 1 | 2010 | 88 | 0.020 |
Why?
| | Luminescent Proteins | 1 | 2010 | 55 | 0.020 |
Why?
| | Microscopy | 1 | 2010 | 57 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2014 | 1013 | 0.020 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2011 | 128 | 0.020 |
Why?
| | Staining and Labeling | 1 | 2010 | 97 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2012 | 636 | 0.020 |
Why?
| | Two-Hybrid System Techniques | 1 | 2009 | 24 | 0.020 |
Why?
| | Virion | 1 | 2009 | 18 | 0.020 |
Why?
| | Cell Survival | 1 | 2012 | 602 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2012 | 466 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2013 | 1581 | 0.020 |
Why?
| | Myeloid Cells | 1 | 2009 | 38 | 0.020 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2009 | 61 | 0.020 |
Why?
| | Genome, Viral | 1 | 2009 | 79 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2012 | 476 | 0.020 |
Why?
| | Antigens, CD | 1 | 2009 | 221 | 0.020 |
Why?
| | Gene Expression | 1 | 2010 | 609 | 0.020 |
Why?
| | NF-kappa B | 1 | 2009 | 315 | 0.020 |
Why?
| | Up-Regulation | 1 | 2009 | 453 | 0.020 |
Why?
| | Mutation | 1 | 2013 | 1294 | 0.020 |
Why?
| | Apoptosis | 1 | 2012 | 1112 | 0.020 |
Why?
| | Female | 2 | 2013 | 26635 | 0.010 |
Why?
|
|
Liu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|